Comparing ozanimod and fingolimod for children with MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study compares two oral medications, ozanimod and fingolimod, to see which one works better and is safer for children and teenagers with relapsing-remitting MS. Both drugs help reduce MS attacks and slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 10 and 17 years old (child or adolescent).
- You have been diagnosed with relapsing-remitting multiple sclerosis (RRMS).
- You have had at least one MS attack in the last year, or two attacks in the last two years, or an MRI showing active MS spots.
- Your disability level is mild to moderate (EDSS score 0 to 5.5).
- You do not have progressive MS or other active immune system diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two oral medications, diroximel fumarate and dimethyl fumarate, in children and teens with relapsing MS. It aims to see if they are safe and can reduce the number of relapses compared to each other.
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
This study checks how safe and effective fingolimod is when adults with relapsing-remitting multiple sclerosis start it for the first time. It may help confirm whether this treatment works well and is tolerated in newly treated patients.
This study looks at how well fingolimod (Gilenya) works in people with relapsing-remitting multiple sclerosis (RRMS) in Greece. If you're already taking this medication, researchers will review your past medical data to see how it affects your MS over time.
This study tests whether people with stable MS who have been on a B-cell depleting therapy for at least 2 years can safely switch to a daily pill called ozanimod. It aims to see if this switch keeps MS under control and may be more convenient.
This trial tests an injectable medication called ocrelizumab for children and teenagers with relapsing-remitting multiple sclerosis. The goal is to see if it is safe and how well it works to control the disease.
Hear when a new Multiple Sclerosis, Relapsing-Remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.